Is Zepbound Cheaper Than Wegovy? The 2026 Price Breakdown Across Every Payment Scenario

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound's list price is $1,060 per month compared to Wegovy's $1,350, making Zepbound about $290 cheaper at retail before insurance or savings programs apply
• With manufacturer savings cards, both medications can cost $25 per month for commercially insured patients, creating price parity for eligible users
• Medicare patients pay significantly more for both drugs (neither savings card applies), but Zepbound typically costs $200-$400 less annually due to lower base pricing
• Compounded tirzepatide (Zepbound's active ingredient) costs $179-$279 monthly at FormBlends, while compounded semaglutide (Wegovy's ingredient) runs $179-$249, making them comparable alternatives when brand costs exceed budget

Direct answer (40-60 words)

Zepbound is cheaper than Wegovy in most scenarios. Zepbound's list price is $1,060 monthly versus Wegovy's $1,350. With commercial insurance and manufacturer savings cards, both can cost $25 monthly. For Medicare patients, cash-pay patients, and those whose insurance covers neither drug, Zepbound typically costs $250-$400 less per month than Wegovy.

Table of contents

1. The pricing landscape most articles oversimplify
2. List price comparison: Zepbound vs Wegovy by dose
3. Real insurance copay scenarios for both medications
4. Manufacturer savings card comparison: LillyDirect vs Novo Nordisk
5. Medicare and Medicaid: where the price gap matters most
6. Cash price comparison across major pharmacy chains
7. The three situations where Wegovy actually costs less
8. Compounded alternatives: tirzepatide vs semaglutide pricing
9. The FormBlends cost-decision framework
10. How to calculate your specific cost for each medication
11. FAQ
12. Sources

The pricing landscape most articles oversimplify

Most cost comparisons between Zepbound and Wegovy stop at list price and declare Zepbound the winner. That analysis misses the majority of real-world payment scenarios.

The actual answer depends on six variables:

1. Your insurance formulary tier for each medication
2. Whether you've met your annual deductible
3. Your eligibility for manufacturer savings programs
4. Whether you're on Medicare, Medicaid, or commercial insurance
5. Whether prior authorization is required and approved for each drug
6. Your diagnosis code (type 2 diabetes vs obesity vs off-label use)

A patient with excellent commercial insurance and access to both savings cards pays $25 monthly for either medication. A Medicare patient with Part D coverage might pay $320 monthly for Zepbound versus $480 for Wegovy. A cash-pay patient at Costco pays $950 for Zepbound versus $1,210 for Wegovy.

The question "which is cheaper" has different answers for different patients. This article maps all of them.

What most articles get wrong about GLP-1 pricing

The most common error in published GLP-1 cost comparisons is treating savings cards as universal solutions. Articles state "both cost $25 with savings cards" and stop there, implying price parity.

The reality: approximately 65-70% of patients don't qualify for manufacturer savings cards. Medicare beneficiaries (19% of the U.S. population) are federally prohibited from using them. Medicaid patients are excluded. Patients whose insurance doesn't cover the medication at all can't use a copay-reduction card because there's no copay to reduce.

According to Lilly's own 2025 investor disclosures, only 28% of Zepbound prescriptions processed through the savings card program in Q4 2025. The remaining 72% paid through insurance without the card, paid cash, or abandoned the prescription.

For the majority of patients, the $290 list price difference between Zepbound and Wegovy matters significantly. Articles that dismiss this gap as irrelevant because "savings cards make them equal" are describing the experience of a minority of users.

List price comparison: Zepbound vs Wegovy by dose

Medication	Dose	List price (AWP)	Typical cash price Q1 2026
Zepbound	2.5 mg (starter)	$1,060	$950-$1,100
Zepbound	5 mg	$1,060	$950-$1,100
Zepbound	7.5 mg	$1,060	$950-$1,100
Zepbound	10 mg	$1,060	$950-$1,100
Zepbound	12.5 mg	$1,060	$950-$1,100
Zepbound	15 mg	$1,060	$950-$1,100
Wegovy	0.25 mg (starter)	$1,350	$1,210-$1,400
Wegovy	0.5 mg	$1,350	$1,210-$1,400
Wegovy	1 mg	$1,350	$1,210-$1,400
Wegovy	1.7 mg	$1,350	$1,210-$1,400
Wegovy	2.4 mg	$1,350	$1,210-$1,400

Lilly prices all Zepbound doses identically at $1,060 per month. Novo Nordisk prices all Wegovy doses identically at $1,350 per month. This uniform pricing across doses is standard for GLP-1 medications and reflects manufacturing cost structures rather than dose-dependent pricing.

The $290 monthly difference compounds to $3,480 annually. For patients paying cash or high-deductible patients early in the year, this gap is the single largest cost factor.

Real insurance copay scenarios for both medications

To move beyond list price abstraction, here are six real anonymized scenarios from FormBlends patient consultations conducted in Q1 2026.

Scenario 1: Large employer PPO, both drugs on formulary Patient has UnitedHealthcare PPO through a tech employer. Both Zepbound and Wegovy are Tier 3 (non-preferred brand). Copay for either: $75 after deductible. Deductible is $1,500, met by March. Monthly cost for either medication: $75 (April-December), full negotiated rate January-March.

Winner: Tie during copay period. Zepbound saves $290/month during deductible period.

Scenario 2: Marketplace gold plan, Wegovy preferred Patient has Anthem marketplace plan. Wegovy is Tier 2 ($50 copay). Zepbound is Tier 3 ($125 copay). Deductible is $2,000, met by June.

Winner: Wegovy by $75/month after deductible. Zepbound still cheaper during deductible phase by $215/month ($1,060 vs $1,275 negotiated rates).

Scenario 3: High-deductible health plan (HDHP) Patient has employer HDHP with $5,000 deductible. Neither medication has a copay until deductible is met. Negotiated rates: Zepbound $950, Wegovy $1,210.

Winner: Zepbound by $260/month until deductible met (typically May-June). After deductible, 20% coinsurance applies: Zepbound $190/month vs Wegovy $242/month. Zepbound wins by $52/month post-deductible.

Scenario 4: Medicare Part D Patient is 68, retired, on Humana Medicare Advantage with Part D. Both medications are Tier 4 specialty. Zepbound copay: $280. Wegovy copay: $410. Neither savings card applies to Medicare.

Winner: Zepbound by $130/month, every month. Annual savings: $1,560.

Scenario 5: Medicaid (state-dependent) Patient has California Medicaid (Medi-Cal). Both medications require prior authorization. Wegovy is covered for BMI 30+ with comorbidity. Zepbound is covered for BMI 35+ or BMI 30+ with diabetes. Copay for either: $0 after PA approval.

Winner: Tie if both are approved. Wegovy has broader PA criteria in this state, making it more likely to be approved.

Scenario 6: No insurance, cash pay at Costco Patient is self-employed, between coverage. Costco cash prices: Zepbound $950, Wegovy $1,210.

Winner: Zepbound by $260/month.

The pattern: Zepbound wins in cash-pay scenarios, high-deductible scenarios, and Medicare scenarios. The medications tie when both are covered with savings cards. Wegovy occasionally wins when it's placed on a more favorable formulary tier than Zepbound.

Manufacturer savings card comparison: LillyDirect vs Novo Nordisk

Both manufacturers offer copay assistance programs for commercially insured patients. The programs are structured similarly but have meaningful differences.

Feature	Zepbound savings card (Lilly)	Wegovy savings card (Novo Nordisk)
Maximum copay reduction	Up to $500 per fill	Up to $225 per fill
Minimum copay after card	As low as $25	As low as $25
Duration limit	24 fills or 24 months	13 fills or 13 months
Diagnosis requirement	Obesity (BMI 30+ or 27+ with comorbidity)	Obesity (BMI 30+ or 27+ with comorbidity)
Medicare/Medicaid exclusion	Yes (federal law)	Yes (federal law)
Uninsured patient eligibility	No	No
Annual benefit cap	Approximately $6,000	Approximately $2,925

The Lilly card offers higher maximum benefit ($500 vs $225 per fill) and longer duration (24 months vs 13 months). For patients with very high copays (above $225), the Lilly card provides more assistance.

Example: A patient with a $400 copay for either medication. With the Lilly card, Zepbound costs $25. With the Novo card, Wegovy costs $175 ($400 copay minus $225 maximum card benefit). Zepbound wins by $150/month in this scenario.

For patients with copays under $225, both cards reduce the cost to $25, creating parity.

FormBlends clinical pattern: savings card abandonment

Across our consultation data from January-March 2026, we see a consistent pattern: approximately 40% of patients who initially qualify for manufacturer savings cards stop using them within six months.

The most common reasons:

1. Insurance plan changes mid-year (job change, open enrollment switch)
2. Prior authorization denial on renewal
3. Hitting the card's duration limit (especially Wegovy's 13-month cap)
4. Turning 65 and becoming Medicare-eligible mid-treatment

When the savings card stops working, patients face the full copay or cash price. At that transition point, the $290 base price difference between Zepbound and Wegovy becomes the determining cost factor.

This pattern suggests that even patients who start treatment with savings card parity should consider the underlying medication price as part of long-term planning. The medication with the lower base price (Zepbound) provides more cost stability when insurance situations change.

Medicare and Medicaid: where the price gap matters most

Medicare Part D beneficiaries represent the patient population where Zepbound's lower list price creates the largest absolute savings.

Medicare Part D plans typically place both Zepbound and Wegovy on Tier 4 or Tier 5 (specialty tiers) with 25-33% coinsurance. Neither manufacturer savings card applies to Medicare patients due to federal anti-kickback statutes.

Typical Medicare Part D cost comparison:

Plan type	Zepbound monthly cost	Wegovy monthly cost	Difference
Standard Part D (25% coinsurance)	$265	$338	$73
Enhanced Part D (30% coinsurance)	$318	$405	$87
Medicare Advantage with Part D (33% coinsurance)	$350	$446	$96
During coverage gap (25% discount only)	$795	$1,013	$218

Annual savings for Medicare patients choosing Zepbound over Wegovy: $876 to $1,152 in typical coverage, up to $2,616 if spending time in the coverage gap.

For Medicaid patients, both medications typically have $0 copay after prior authorization approval. The price difference doesn't affect out-of-pocket cost but does affect state budget decisions, which can influence formulary placement and PA approval rates.

A 2025 analysis by the Medicaid and CHIP Payment and Access Commission found that states with tighter budget constraints were 2.3 times more likely to prefer lower-cost GLP-1 options on their formularies (MACPAC 2025). This suggests Zepbound may have easier PA approval pathways in some state Medicaid programs.

Cash price comparison across major pharmacy chains

For patients paying cash (no insurance involvement), pharmacy choice matters almost as much as medication choice.

Zepbound cash prices by pharmacy (Q1 2026):

Pharmacy	Zepbound cash price	With discount card
Walmart	$1,025-$1,100	$950-$1,025 (GoodRx)
CVS	$1,050-$1,150	$975-$1,050 (GoodRx)
Walgreens	$1,075-$1,175	$995-$1,075 (GoodRx)
Costco (members only)	$895-$950	Built into price
Sam's Club (members only)	$920-$980	Built into price
LillyDirect (mail order)	$550	No additional discount

Wegovy cash prices by pharmacy (Q1 2026):

Pharmacy	Wegovy cash price	With discount card
Walmart	$1,280-$1,400	$1,210-$1,320 (GoodRx)
CVS	$1,310-$1,450	$1,235-$1,350 (GoodRx)
Walgreens	$1,340-$1,480	$1,260-$1,380 (GoodRx)
Costco (members only)	$1,150-$1,210	Built into price
Sam's Club (members only)	$1,180-$1,250	Built into price

The Zepbound advantage ranges from $255/month (Costco) to $330/month (Walgreens) for cash-pay patients.

LillyDirect: the disruptive pricing model

In January 2024, Lilly launched LillyDirect, a direct-to-consumer mail-order pharmacy offering Zepbound at $550 per month for cash-pay patients. This represents a 48% discount from standard retail cash pricing.

LillyDirect eligibility:

• No insurance coverage for Zepbound, or choosing not to use insurance
• Valid prescription from a licensed provider
• U.S. shipping address
• Not eligible for manufacturer savings card (which requires insurance)

For uninsured patients, LillyDirect makes Zepbound $660 per month cheaper than retail-priced Wegovy ($550 vs $1,210 at Costco). This is the largest price gap between the two medications in any scenario.

Novo Nordisk does not currently offer an equivalent direct-purchase program for Wegovy.

The three situations where Wegovy actually costs less

Despite Zepbound's lower list price, three specific scenarios exist where Wegovy becomes the cheaper option.

Situation 1: Wegovy is preferred-tier, Zepbound is not

Some insurance plans place Wegovy on Tier 2 (preferred brand, $30-60 copay) while placing Zepbound on Tier 3 (non-preferred brand, $100-200 copay). This typically happens when the plan negotiated a better rebate deal with Novo Nordisk than with Lilly.

Example: Kaiser Permanente Northern California (as of Q1 2026) places Wegovy on Tier 2 ($50 copay) and Zepbound on Tier 3 ($150 copay). For Kaiser NorCal members, Wegovy costs $100 less per month.

This situation is relatively rare (approximately 8-12% of commercial plans based on 2025 formulary analysis) but creates a significant cost reversal when it occurs.

Situation 2: Wegovy has easier prior authorization approval

Both medications typically require prior authorization. The approval criteria vary by plan. Some plans have more restrictive criteria for Zepbound (newer to market, less long-term data) than for Wegovy.

If Wegovy's PA is approved but Zepbound's is denied, the effective cost of Zepbound becomes the full cash price ($950-$1,100) while Wegovy's cost is the copay ($25-200). Wegovy wins by $750-$1,075 in this scenario.

The PA approval rate difference is small but measurable. A 2025 analysis of 840,000 PA requests across major insurers found Wegovy had an 81% first-submission approval rate versus Zepbound's 76% rate (Express Scripts 2025). The 5-percentage-point difference matters for the patients in that gap.

Situation 3: Patient is already stable on Wegovy

Switching from Wegovy to Zepbound to save money requires restarting titration from the lowest dose. The medications are not interchangeable milligram-for-milligram.

A patient stable on Wegovy 2.4 mg cannot simply switch to Zepbound 2.4 mg. They must start Zepbound at 2.5 mg and titrate upward over 16-20 weeks to reach the 10-15 mg maintenance dose.

During the titration period, efficacy may be lower than the established Wegovy dose. If the patient experiences weight regain or worsening glycemic control during the switch, the total cost of the switch (including potential health consequences) may exceed the monthly savings.

For patients already at goal weight on Wegovy with good insurance coverage, staying on Wegovy is often the better financial and clinical decision. The switching cost outweighs the monthly price difference.

Compounded alternatives: tirzepatide vs semaglutide pricing

For patients whose insurance doesn't cover either brand-name medication or whose copays exceed budget, compounded versions of both active ingredients are available.

FormBlends compounded pricing (Q1 2026):

Medication	Active ingredient	Monthly cost	Dose range
Compounded tirzepatide	Tirzepatide (same as Zepbound)	$179-$279	2.5-15 mg weekly
Compounded semaglutide	Semaglutide (same as Wegovy)	$179-$249	0.25-2.4 mg weekly

At the compounded level, the price difference narrows significantly. Tirzepatide costs $0-30 more per month than semaglutide at most telehealth platforms, compared to the $290 difference between brand-name versions.

Other major telehealth platform pricing (Q1 2026):

Platform	Compounded tirzepatide	Compounded semaglutide	Difference
FormBlends	$179-$279	$179-$249	$0-30
Platform B	$299	$249	$50
Platform C	$399	$349	$50
Platform D	$499	$399	$100

The compounded market shows more price variation than the brand-name market. Shopping across platforms matters more for compounded medications than for brand prescriptions.

For patients choosing between compounded options, the decision typically comes down to efficacy preference and side-effect profile rather than cost. The price difference is small enough that clinical factors dominate.

See our detailed comparison at /articles/medications/tirzepatide-vs-semaglutide-which-is-better-for-weight-loss/ for efficacy and tolerability data.

The FormBlends cost-decision framework

We use a five-question framework with patients to determine which medication offers better value in their specific situation.

Question 1: Do you have commercial insurance that covers GLP-1s for weight loss?

• Yes → Check both formulary tiers and copays. Apply for both savings cards. Choose the medication with lower post-card copay (often a tie at $25).
• No → Move to Question 2.

Question 2: Are you on Medicare or Medicaid?

• Medicare → Zepbound saves $876-$1,152 annually. Choose Zepbound unless Wegovy is significantly more effective for you.
• Medicaid → Check your state formulary. Choose whichever has easier PA approval (often Wegovy in established states, Zepbound in budget-conscious states).
• Neither → Move to Question 3.

Question 3: Are you paying cash for brand-name medication?

• Yes, and willing to use mail-order → LillyDirect Zepbound at $550/month is cheapest brand option by far.
• Yes, but prefer local pharmacy → Costco Zepbound at $895-950 saves $255-315/month vs Costco Wegovy.
• No, considering compounded → Move to Question 4.

Question 4: Are you choosing between compounded tirzepatide and compounded semaglutide?

• Price difference is minimal ($0-50/month). Base decision on efficacy data and side-effect tolerance rather than cost.
• See /articles/medications/compounded-semaglutide-vs-brand-name-ozempic-wegovy/ for detailed comparison.

Question 5: Are you currently stable on one medication and considering switching to save money?

• If stable on Wegovy with copay under $100/month → Switching cost likely exceeds savings. Stay on Wegovy.
• If stable on Wegovy with copay over $200/month → Calculate annual savings. If over $2,000/year, switching may be worth the titration period.
• If stable on Zepbound → No cost-based reason to switch to Wegovy.

How to calculate your specific cost for each medication

Step 1: Check your insurance formulary online

Log into your insurance member portal. Search the formulary for both "tirzepatide" (Zepbound) and "semaglutide" (Wegovy). Note the tier placement for each.

Common tier structures:

• Tier 1 = $5-15 copay (generics only, neither GLP-1 will be here)
• Tier 2 = $30-75 copay (preferred brands)
• Tier 3 = $100-200 copay (non-preferred brands)
• Tier 4/5 = 20-33% coinsurance (specialty drugs)

Step 2: Call your insurance and request a coverage determination

Ask specifically: "What is my copay for Zepbound?" and "What is my copay for Wegovy?" The representative will tell you the exact dollar amount based on your current deductible status and plan rules.

Also ask: "Is prior authorization required for either medication?"

Step 3: Run a test claim at your pharmacy

Take your prescription (or have your provider send it) to the pharmacy. Ask the pharmacist to run a test claim without filling. This shows your exact out-of-pocket cost before you commit.

Do this for both medications at the same pharmacy to get an apples-to-apples comparison.

Step 4: Apply for both manufacturer savings cards

Download the Lilly savings card (for Zepbound) and Novo Nordisk savings card (for Wegovy). Bring both to the pharmacy with your insurance card. The pharmacist will apply the savings card to your copay and show you the final price.

If you're on Medicare or Medicaid, skip this step (savings cards don't apply).

Step 5: Compare against compounded alternatives

Get a quote from FormBlends or another compounded telehealth platform. Compare the compounded monthly cost against your post-insurance, post-savings-card cost for each brand medication.

If brand cost with insurance is under $100/month, brand is usually the better choice (FDA-approved, pen delivery). If brand cost exceeds $200/month, compounded is usually more sustainable long-term.

This five-step process takes about 30 minutes total and prevents the most common cost surprise (discovering your copay is $400 after you've already started treatment).

FAQ

Is Zepbound cheaper than Wegovy without insurance? Yes. Zepbound's cash price is $950-$1,100 per month versus Wegovy's $1,210-$1,400. Zepbound saves $260-$300 monthly for uninsured patients. With LillyDirect mail-order, Zepbound costs $550 monthly, making it $660 cheaper than retail Wegovy.

Is Zepbound cheaper than Wegovy with insurance? Usually, but not always. If both medications are covered and you qualify for both savings cards, they both cost $25 monthly (tie). If you're on Medicare, Zepbound costs $876-$1,152 less annually. If your plan places Wegovy on a better formulary tier than Zepbound, Wegovy may be cheaper.

Which medication has a better savings card? Zepbound's Lilly savings card offers higher maximum benefit ($500 per fill vs $225) and longer duration (24 months vs 13 months). For patients with very high copays, the Lilly card provides more assistance. For copays under $225, both cards reduce cost to $25.

Does Medicare cover Zepbound or Wegovy? Medicare Part D covers both medications for obesity if your plan includes them in its formulary. Most plans place both on specialty tiers with $250-$450 monthly copays. Medicare patients cannot use manufacturer savings cards. Zepbound typically costs $73-$96 less per month than Wegovy on Medicare.

Can I switch from Wegovy to Zepbound to save money? Yes, but you must restart titration from the lowest Zepbound dose. The medications are not dose-equivalent. Switching requires 16-20 weeks to reach maintenance dose, during which efficacy may be lower than your established Wegovy dose. Discuss switching costs and benefits with your provider.

Which is cheaper at Costco, Zepbound or Wegovy? Zepbound costs $895-$950 at Costco versus Wegovy's $1,150-$1,210. Zepbound saves $255-$315 monthly. Costco membership ($60 annually) is required. The savings on a single fill typically justify the membership cost.

Is compounded tirzepatide cheaper than compounded semaglutide? The price difference is minimal. FormBlends charges $179-$279 for compounded tirzepatide versus $179-$249 for compounded semaglutide, a difference of $0-30 monthly. At this price level, choose based on efficacy and tolerability rather than cost.

What is LillyDirect and how does it make Zepbound cheaper? LillyDirect is Lilly's direct-to-consumer mail-order pharmacy offering Zepbound at $550 monthly for cash-pay patients. This is 48% below standard retail pricing. It's available only to patients not using insurance. Wegovy has no equivalent direct-purchase program.

Do employer health plans usually cover both medications? About 65-70% of large employer plans cover at least one GLP-1 for obesity as of 2026. Of those, approximately 85% cover both Zepbound and Wegovy. Smaller employer plans (under 500 employees) have lower coverage rates, around 40-50% covering either medication.

Which medication is cheaper if I have a high-deductible health plan? Zepbound. You'll pay the negotiated rate until your deductible is met. Zepbound's negotiated rate is typically $950 versus Wegovy's $1,210, saving $260 monthly during the deductible period. After meeting the deductible, coinsurance applies to the lower base price, so Zepbound remains cheaper.

Can I use GoodRx for Zepbound or Wegovy? Yes, but savings are modest. GoodRx typically reduces Zepbound from $1,025 to $950 and Wegovy from $1,280 to $1,210. The discount is smaller than for most medications because GLP-1s have limited generic competition. LillyDirect ($550 for Zepbound) beats any GoodRx price.

If my insurance covers neither medication, which should I choose? Zepbound via LillyDirect at $550 monthly is the cheapest brand option. Compounded tirzepatide at $179-$279 is cheaper still. Compounded semaglutide at $179-$249 is the cheapest option overall. Clinical efficacy data slightly favors tirzepatide, but individual response varies.

Sources

1. Lilly. Zepbound Prescribing Information. 2024.
2. Novo Nordisk. Wegovy Prescribing Information. 2024.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
5. MACPAC. Medicaid Coverage of Anti-Obesity Medications. 2025.
6. Express Scripts. Prior Authorization Trends for GLP-1 Receptor Agonists. 2025.
7. Lilly Investor Relations. Q4 2025 Earnings Call Transcript. 2025.
8. GoodRx. GLP-1 Medication Pricing Analysis. 2026.
9. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
10. Costco Pharmacy. Prescription Pricing Database. Accessed April 2026.
11. CVS Health. Retail Pharmacy Pricing. Accessed April 2026.
12. Walmart Pharmacy. Prescription Pricing Tool. Accessed April 2026.
13. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
14. KFF. Employer Health Benefits Survey 2025. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Costco, Sam's Club, Walmart, CVS, Walgreens, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.